NF-E2-related factor 2 and its role in diabetic nephropathy

Iranian Journal of Kidney Diseases

Volumn 7, Issue 5, 2013, Pages 346-351

  Dadras, Farahnaz ^a   Khoshjou, Farhad ^a  

^a Hamadan University of Medical Sciences   (Iran)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Nf E2 related factor 2; Oxidative stress

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; BARDOXOLONE; CHROMIUM DERIVATIVE; CHROMIUM HISTIDINATE; CHROMIUM PICOLINATE; CYSTEINE; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTAMATE CYSTEINE LIGASE; KALLIKREIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PLACEBO; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SMALL INTERFERING RNA; SULFORAPHANE; SUPEROXIDE DISMUTASE; TELMISARTAN; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CHRONIC KIDNEY DISEASE; DEFENSE MECHANISM; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG TISSUE LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GLOMERULUS FILTRATION RATE; GLYCEROL BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; MESANGIUM CELL; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UBIQUITINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; CYTOSKELETAL PROTEINS; DIABETIC NEPHROPATHIES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOTHIOCYANATES; MICE; NF-E2-RELATED FACTOR 2;

EID: 84884744300     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358-1373.
3. Champe PC, Harvey RA, Ferrier DR, editors. Lippincott's illustrated reviews: biochemistry. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
4. Sen CK. Antioxidant and redox regulation of cellular signaling: introduction. Med Sci Sports Exerc. 2001;33:368-370.
5. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081.
6. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
7. Sykiotis GP, Habeos IG, Samuelson AV, Bohmann D. The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab Care. 2011;14:41-48.
8. Wardle EN. Cellular oxidative processes in relation to renal disease. Am J Nephrol. 2005;25:13-22.
9. Kazemi Arababadi M. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis. 2010;4:302-306.
10. Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Nezami N, Safa J, Montazer-Saheb S. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy. Iran J Kidney Dis. 2009;3:93-98.
11. Choudhary N, Ahlawat RS. Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis. 2008;2:72-79.
12. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol. 2003;14:S227-S232.
13. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes. 2006;55:3112-3120.
14. Moon JY, Tanimoto M, Gohda T, et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P) H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol. 2011;300:F1271-F1282.
15. Calkins MJ, Johnson DA, Townsend JA, et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal. 2009;11:497-508.
16. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89-116.
17. Kobayashi M, Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul. 2006;46:113-140.
18. Sykiotis GP, Bohmann D. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal. 2010;3:re3.
19. Lee JM, Li J, Johnson DA, et al. Nrf2, a multi-organ protector? FASEB J. 2005;19:1061-1066.
20. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC. Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res. 2007;75:261-274.
21. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem. 2006;281:24756-24768.
22. de Haan JB. Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes. 2011;60:2683-4.
23. Kobayashi M, Li L, Iwamoto N, et al. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol. 2009;29:493-502.
24. Tong KI, Padmanabhan B, Kobayashi A, et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol. 2007;27:7511-7521.
25. Holland R, Hawkins AE, Eggler AL, Mesecar AD, Fabris D, Fishbein JC. Prospective type 1 and type 2 disulfides of Keap1 protein. Chem Res Toxicol. 2008;21:2051-2060.
26. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59:850-860.
27. Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008;13:1159-1170.
28. Li H, Wang F, Zhang L, et al. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal. 2011;23:1625-1632.
29. Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol. 2009;112:e31-e42.
30. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley PJ. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 2008;57:2809-2817.
31. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506.
32. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005;102:4584-4589.
33. Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6:154-162.
34. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol. 1999;37:973-979.
35. Clarke JD, Hsu A, Williams DE, et al. Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice. Pharm Res. 2011;28:3171-3179.
36. Shin DH, Park HM, Jung KA, et al. The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med. 2010;48:1051-1063.
37. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW, Park BH. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol. 2008;75:2214-2223.
38. Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011;60:3055-3066.
39. Cui W, Bai Y, Miao X, et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev. 2012;2012:821936.
40. Kim SB, Eskiocak U, Ly P, et al. Bardoxolone-methyl-CDDO-Me: an antioxidant, anti-inflammatory modulator is a novel radiation countermeasure and mitigator. Proceedings of the 22nd Annual NASA Space Radiation Inves tigators' Workshop; 2011.
41. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33:469-476.
42. de Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013;37:212-222.
43. Zoja C, Corna D, Nava V, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol. 2013;304:F808-F819.
44. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011;1812:719-731.
45. Selcuk MY, Aygen B, Dogukan A, et al. Chromium picolinate and chromium histidinate protects against renal dysfunction by modulation of NF-kappaB pathway in high-fat diet fed and Streptozotocin-induced diabetic rats. Nutr Metab (Lond). 2012;9:30.
46. Fujita H, Fujishima H, Morii T, et al. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice. Hypertens Res. 2012;35:213-220.